Tissue Repair During Acute Phase of Myocardial Infarction

描述（由申请人提供）：心肌梗死急性期的组织修复心血管疾病是发达国家死亡率和发病率的主要原因。每年，全世界发生超过1900万起突发心脏事件，其中约100万起发生在美国。急性冠状动脉综合征（ACS）患者患有一系列急性心肌缺血状态。溶栓和经皮介入治疗（PCI）用于缺血组织的再灌注和稳定梗死引起的损伤。在急性心肌梗死（AMI）后，受影响的缺血组织经历由坏死和凋亡引起的细胞死亡，随后是炎症和导致瘢痕组织形成的肉芽化过程。AMI后的这段时间为挽救受损的心肌组织和预防纤维化提供了一个关键而独特的机会。该项目的目标是开发一种新的基于蛋白质的治疗方法，以拯救心肌组织免于凋亡，减少炎症和纤维化，并恢复AMI后的心脏功能。 公共卫生相关性：心肌梗死急性期的组织修复心血管疾病是发达国家死亡率和发病率的主要原因。急性心肌梗死（AMI）影响全世界1900万人，其中大量患有心力衰竭。本项目的目标是开发一种新的治疗方法，该方法将显著促进AMI后心脏功能的恢复，从而大大降低死亡率，同时改善受影响患者的生活质量。

DESCRIPTION (provided by applicant): Tissue Repair During Acute Phase of Myocardial Infarction Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Each year, over 19 million incidents of sudden cardiac events occur worldwide, with approximately 1 million of those in the United States. Patients with acute coronary syndrome (ACS) suffer from a range of acute myocardial ischemic states. Thrombolysis and percutaneous intervention (PCI) are used to reperfuse the ischemic tissue and stabilize damage caused by infarction. After acute myocardial infarction (AMI), affected ischemic tissues undergo cell death from necrosis and apoptosis, followed by inflammation and a process of granulation leading to scar tissue formation. The period immediately following AMI provides a critical and unique opportunity to rescue damaged myocardial tissues and prevent fibrosis. The goal of this project is to develop a novel protein based therapy to rescue heart tissue from apoptosis, reduce inflammation and fibrosis, and restore cardiac function after AMI. PUBLIC HEALTH RELEVANCE: Tissue Repair During Acute Phase of Myocardial Infarction Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Acute myocardial infarction (AMI) affects 19 million people worldwide, with a large number suffering from heart failure. To goal of this project is to develop a novel therapy that will significantly enhance the recovery of heart function after AMI and thereby greatly reduce the level of mortality while improving quality of life of affected patients.